Solvo Biotechnology
The leading provider of transporter services and products of drugs.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 18 % | 35 % | 20 % | 2 % | 31 % | 31 % | 34 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 19 % | 24 % | 24 % | 15 % | 37 % | 38 % | 58 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 7 % | 11 % | 15 % | 7 % | 30 % | 31 % | 50 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
SOLVO Biotechnology, a Charles River company, specializes in providing comprehensive drug transporter services that adhere to FDA and EMA guidelines for drug interaction studies. The company serves pharmaceutical and biotechnology firms, offering a range of assays and transporter kits to support drug development and regulatory compliance. Operating in the global pharmaceutical market, SOLVO generates revenue through service fees and product sales, including licensing agreements. The business model focuses on continuous innovation, launching 10-20 new products annually to meet industry needs and regulatory requirements.
Keywords: drug transporter services, FDA compliance, EMA guidelines, pharmaceutical industry, drug interaction studies, assays, transporter kits, regulatory compliance, innovation, licensing.